Medimmune Oncology patents expiration
1. Neutrexin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6017922 | MEDIMMUNE ONCOLOGY | Thermally stable trimetrexates and processes for producing the same |
May, 2018
(6 years ago) | |
Drugs and Companies using TRIMETREXATE GLUCURONATE ingredient
Market Authorisation Date: 17 December, 1993
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
NEUTREXIN family patents
